Biocryst Pharmaceuticals (BCRX) Income from Continuing Operations (2010 - 2026)

Biocryst Pharmaceuticals (BCRX) has 17 years of Income from Continuing Operations data on file, last reported at 721812000.0 in Q1 2026.

• Quarterly Income from Continuing Operations fell 2255762.5% year-over-year to 721812000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 457983000.0 (down 756.52% YoY) and the FY2025 annual result came in at 263861000.0, up 396.87% from the prior year.
• Income from Continuing Operations fell to 721812000.0 in Q1 2026, from 245845000.0 in the prior quarter.
• In the past five years, Income from Continuing Operations ranged from a high of 245845000.0 in Q4 2025 to a low of 721812000.0 in Q1 2026.
• A 5-year average of 60028647.06 and a median of 36149000.0 in 2023 frame the typical range for Income from Continuing Operations.
• Annual changes were most pronounced in 2025 — Income from Continuing Operations surged 1017.5% — and 2026, when it tumbled 2255762.5%.
• Tracing BCRX's Income from Continuing Operations over 5 years: stood at 71541000.0 in 2022, then increased by 13.71% to 61731000.0 in 2023, then surged by 56.59% to 26795000.0 in 2024, then surged by 1017.5% to 245845000.0 in 2025, then tumbled by 393.6% to 721812000.0 in 2026.
• The last three Income from Continuing Operations figures came in at 721812000.0 (Q1 2026), 245845000.0 (Q4 2025), and 12899000.0 (Q3 2025), per Business Quant data.